{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:43:00Z","timestamp":1790217780279,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Attention-deficit\/hyperactivity disorder (ADHD) is a common neurobehavioral disorder affecting approximately 10.0% of children and 6.5% of adolescents in the United States (US). A comprehensive assessment of the current treatment landscape is warranted to highlight potential unmet needs of children and adolescents with ADHD. Therefore, this study described treatment patterns and healthcare costs among commercially insured children and adolescents with ADHD in the US.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Children and adolescents with ADHD initiating pharmacological treatment indicated for ADHD were identified from IBM MarketScan Commercial Database (2014\u20132018). A treatment sequence algorithm was used to examine treatment patterns, including discontinuation (\u2265\u2009180\u00a0days following the last day of supply of any ADHD treatment), switch, add-on, and drop (discontinuation of an agent in combination therapy), during the 12-month study period following the index date (i.e., first observed ADHD treatment). Total adjusted annual healthcare costs were compared between patients with and without treatment changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 49,756 children and 29,093 adolescents included, mean age was 9 and 15\u00a0years, respectively, and 31% and 38% were female. As the first treatment regimen observed, 92% of both children and adolescents initiated a stimulant and 11% initiated combination therapy. Over half of the population had a treatment change over 12\u00a0months\u201459% of children and 68% of adolescents. Treatment discontinuation over 12\u00a0months was common in both populations\u201421% of children and 36% of adolescents discontinued treatment. Healthcare costs increased with the number of treatment changes observed; children and adolescents with treatment changes (i.e., 1, 2, or\u2009\u2265\u20093) incurred an incremental annual cost of up to $1,443 and $2,705, respectively, compared to those without a treatment change (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Costs were largely driven by outpatient visits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Over a 12-month period, treatment changes were commonly observed and were associated with excess costs, highlighting the unmet treatment needs of children and adolescents with ADHD in the US.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04188-4","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T11:05:20Z","timestamp":1660820720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Treatment patterns among children and adolescents with attention-deficit\/hyperactivity disorder in the United States \u2013 a retrospective claims analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Jeff","family":"Schein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"4188_CR1","unstructured":"Child and adolescent health measurement initiative. 2018\u00a0national survey of children\u2019s health (NSCH) data query. Data resource center for child and adolescent health supported by the U.S. Department of health and human services, health resources and services administration (HRSA), maternal and child health bureau (MCHB). Available from: www.childhealthdata.org. Accessed: 26 Feb.\u00a02020."},{"issue":"4","key":"4188_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/archgenpsychiatry.2011.160","volume":"69","author":"RC Kessler","year":"2012","unstructured":"Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry. 2012;69(4):372\u201380.","journal-title":"Arch Gen Psychiatry"},{"key":"4188_CR3","doi-asserted-by":"crossref","unstructured":"Wolraich ML, Hagan JF, Jr., Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.","DOI":"10.1542\/peds.2019-2528"},{"key":"4188_CR4","unstructured":"Children and adults with attention-deficit\/hyperactivity disorder (CHADD). About ADHD. Lanham;\u00a02017. Available from: https:\/\/chadd.org\/wp-content\/uploads\/2018\/03\/aboutADHD.pdf. Accessed 2 Sept 2021."},{"issue":"3","key":"4188_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jpsychires.2010.06.014","volume":"45","author":"J Breslau","year":"2011","unstructured":"Breslau J, Miller E, Joanie Chung WJ, Schweitzer JB. Childhood and adolescent onset psychiatric disorders, substance use, and failure to graduate high school on time. J Psychiatr Res. 2011;45(3):295\u2013301.","journal-title":"J Psychiatr Res"},{"key":"4188_CR6","first-page":"169","volume-title":"Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment","author":"GJ DuPaul","year":"2015","unstructured":"DuPaul GJ, Langberg JM. Educational impairments in children with ADHD. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: The Guilford Press; 2015. p. 169\u201390."},{"issue":"9","key":"4188_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10802-020-00666-z","volume":"48","author":"TJ Dekkers","year":"2020","unstructured":"Dekkers TJ, Popma A, Sonuga-Barke EJS, Oldenhof H, Bexkens A, Jansen BRJ, et al. Risk taking by adolescents with attention-deficit\/hyperactivity disorder (ADHD): a behavioral and psychophysiological investigation of peer influence. J Abnorm Child Psychol. 2020;48(9):1129\u201341.","journal-title":"J Abnorm Child Psychol"},{"issue":"8","key":"4188_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10802-019-00518-5","volume":"47","author":"X Zhao","year":"2019","unstructured":"Zhao X, Page TF, Altszuler AR, Pelham WE 3rd, Kipp H, Gnagy EM, et al. Family burden of raising a child with ADHD. J Abnorm Child Psychol. 2019;47(8):1327\u201338.","journal-title":"J Abnorm Child Psychol"},{"key":"4188_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/NDT.S121391","volume":"13","author":"M Fridman","year":"2017","unstructured":"Fridman M, Banaschewski T, Sikirica V, Quintero J, Erder MH, Chen KS. Factors associated with caregiver burden among pharmacotherapy-treated children\/adolescents with ADHD in the Caregiver Perspective on Pediatric ADHD survey in Europe. Neuropsychiatr Dis Treat. 2017;13:373\u201386.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"4188_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s10567-019-00274-4","volume":"22","author":"CT Gordon","year":"2019","unstructured":"Gordon CT, Fabiano GA. The transition of youth with ADHD into the workforce: review and future directions. Clin Child Fam Psychol Rev. 2019;22(3):316\u201347.","journal-title":"Clin Child Fam Psychol Rev"},{"issue":"2","key":"4188_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","volume":"179","author":"MH Sibley","year":"2022","unstructured":"Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable patterns of remission from ADHD in the Multimodal Treatment Study of ADHD. Am J Psychiatry. 2022;179(2):142\u201351.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"4188_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/15374416.2017.1417860","volume":"47","author":"ML Danielson","year":"2018","unstructured":"Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents\u00a02016. J Clin Child Adolesc Psychol. 2018;47(2):199\u2013212.","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"9","key":"4188_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"4188_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1176\/appi.ps.201800515","volume":"70","author":"J Biederman","year":"2019","unstructured":"Biederman J, Fried R, DiSalvo M, Storch B, Pulli A, Woodworth KY, et al. Evidence of low adherence to stimulant medication among children and youths with ADHD: an electronic health records study. Psychiatr Serv. 2019;70(10):874\u201380.","journal-title":"Psychiatr Serv"},{"key":"4188_CR15","first-page":"1543","volume":"10","author":"K Gajria","year":"2014","unstructured":"Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543\u201369.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"4188_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"14","key":"4188_CR17","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1517\/14656566.2013.818977","volume":"14","author":"N Warikoo","year":"2013","unstructured":"Warikoo N, Faraone SV. Background, clinical features and treatment of attention deficit hyperactivity disorder in children. Expert Opin Pharmacother. 2013;14(14):1885\u2013906.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 2","key":"4188_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1185\/03007995.2011.623158","volume":"27","author":"P Hodgkins","year":"2011","unstructured":"Hodgkins P, Sasane R, Christensen L, Harley C, Liu F. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin. 2011;27(Suppl 2):53\u201362.","journal-title":"Curr Med Res Opin"},{"key":"4188_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1744-859X-5-5","volume":"5","author":"JE Kemner","year":"2006","unstructured":"Kemner JE, Lage MJ. Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry. 2006;5:5.","journal-title":"Ann Gen Psychiatry"},{"issue":"9","key":"4188_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.18553\/jmcp.2012.18.9.676","volume":"18","author":"V Sikirica","year":"2012","unstructured":"Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, et al. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm. 2012;18(9):676\u201389.","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"4188_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/1087054718816176","volume":"25","author":"L Guo","year":"2021","unstructured":"Guo L, Danielson M, Cogan L, Hines L, Armour B. Treatment patterns and costs among children aged 2 to 17 years with ADHD in New York State Medicaid in 2013. J Atten Disord. 2021;25(4):463\u201372.","journal-title":"J Atten Disord"},{"key":"4188_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-244X-9-54","volume":"9","author":"DE Faries","year":"2009","unstructured":"Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9:54.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"4188_CR23","doi-asserted-by":"publisher","first-page":"A120","DOI":"10.1016\/j.jval.2015.03.705","volume":"18","author":"V Perez","year":"2015","unstructured":"Perez V, Gauthier G, Guerin A, Francois C, Merikle E. The burden of treatment switch in patients with major depression: a US retrospective administrative claims analysis. Value in Health. 2015;18(3):A120.","journal-title":"Value in Health"},{"key":"4188_CR24","unstructured":"IBM Watson Health. IBM Market Scan Research Databases for life sciences researchers 2021. Available from: https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO. Accessed: 17 May\u00a02022."},{"issue":"11","key":"4188_CR25","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1080\/03007995.2021.1968814","volume":"37","author":"J Schein","year":"2021","unstructured":"Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, et al. Treatment patterns among adults with attention-deficit\/hyperactivity disorder in the United States: a retrospective claims study. Curr Med Res Opin. 2021;37(11):2007\u201314.","journal-title":"Curr Med Res Opin."},{"key":"4188_CR26","unstructured":"US Bureau of Labor Statistics. Measuring Price Change in the CPI: Medical care 2019. Available from: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm. Accessed:\u00a0 17 May 2022."},{"issue":"2","key":"4188_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.18553\/jmcp.2004.10.2.122","volume":"10","author":"A Perwien","year":"2004","unstructured":"Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit\/hyperactivity disorder. J Manag Care Pharm. 2004;10(2):122\u20139.","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"4188_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/1044546041649066","volume":"14","author":"S Martins","year":"2004","unstructured":"Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol. 2004;14(2):195\u2013206.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"4188_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/camh.12156","volume":"21","author":"K Ibrahim","year":"2016","unstructured":"Ibrahim K, Vogt C, Donyai P. Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child Adolesc Ment Health. 2016;21(4):192\u2013200.","journal-title":"Child Adolesc Ment Health"},{"issue":"2","key":"4188_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaac.2019.12.009","volume":"60","author":"JC Blader","year":"2021","unstructured":"Blader JC, Pliszka SR, Kafantaris V, Foley CA, Carlson GA, Crowell JA, et al. Stepped treatment for attention-deficit\/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization. J Am Acad Child Adolesc Psychiatry. 2021;60(2):236\u201351.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"17","key":"4188_CR31","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.12998\/wjcc.v7.i17.2420","volume":"7","author":"S Gnanavel","year":"2019","unstructured":"Gnanavel S, Sharma P, Kaushal P, Hussain S. Attention deficit hyperactivity disorder and comorbidity: a review of literature. World J Clin Cases. 2019;7(17):2420\u20136.","journal-title":"World J Clin Cases"},{"issue":"Suppl 2S","key":"4188_CR32","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1097\/DBP.0000000000000781","volume":"41","author":"WJ Barbaresi","year":"2020","unstructured":"Barbaresi WJ, Campbell L, Diekroger EA, Froehlich TE, Liu YH, O\u2019Malley E, et al. The society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit\/hyperactivity disorder: process of care algorithms. J Dev Behav Pediatr. 2020;41(Suppl 2S):S58\u201374.","journal-title":"J Dev Behav Pediatr"},{"issue":"11","key":"4188_CR33","doi-asserted-by":"publisher","first-page":"e1459","DOI":"10.4088\/JCP.14r09478","volume":"76","author":"E Frank","year":"2015","unstructured":"Frank E, Ozon C, Nair V, Othee K. Examining why patients with attention-deficit\/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015;76(11):e1459\u201368.","journal-title":"J Clin Psychiatry"},{"key":"4188_CR34","unstructured":"US Government Accountability Office (GAO). Drug shortages: better management of the quota process for controlled substances needed; coordination between DEA and FDA should be improved. Washington, DC; 2015. Available from: https:\/\/www.gao.gov\/assets\/gao-15-202.pdf. Accessed 26 July 2021."},{"issue":"6","key":"4188_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1089\/cap.2008.0146","volume":"19","author":"P Atzori","year":"2009","unstructured":"Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol. 2009;19(6):673\u201381.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"4188_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/cap.2010.0107","volume":"21","author":"CY Chen","year":"2011","unstructured":"Chen CY, Yeh HH, Chen KH, Chang IS, Wu EC, Lin KM. Differential effects of predictors on methylphenidate initiation and discontinuation among young people with newly diagnosed attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(3):265\u201373.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"4188_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1087054714539997","volume":"20","author":"JR Holbrook","year":"2016","unstructured":"Holbrook JR, Cuffe SP, Cai B, Visser SN, Forthofer MS, Bottai M, et al. Persistence of parent-reported ADHD symptoms from childhood through adolescence in a community sample. J Atten Disord. 2016;20(1):11\u201320.","journal-title":"J Atten Disord"},{"issue":"5","key":"4188_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CHI.0b013e31819c23d0","volume":"48","author":"BSG Molina","year":"2009","unstructured":"Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484\u2013500.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"4188_CR39","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaac.2012.07.008","volume":"51","author":"JA Doshi","year":"2012","unstructured":"Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, et al. Economic impact of childhood and adult attention-deficit\/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990-1002 e2.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"4188_CR40","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jval.2021.04.034","volume":"24","author":"LA Adler","year":"2021","unstructured":"Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, et al. Economic burden of attention-deficit\/hyperactivity disorder (ADHD) among children and adolescents in the United States (US): a societal perspective. Value in Health. 2021;24(1):S6\u20137.","journal-title":"Value in Health"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04188-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04188-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T11:07:23Z","timestamp":1660820843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04188-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4188"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04188-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act. This study does not contain any patient-identifiable information; therefore, no institutional review board exemption nor informed consent was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. AC received research support from Allergan, Takeda\/Shire, Emalex, Akili, Ironshore, Arbor, Aevi Genomic Medicine, Neos Therapeutics, Otsuka, Pfizer, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, and the U.S. Food and Drug Administration; was on the advisory board of Takeda\/Shire, Akili, Arbor, Cingulate, Ironshore, Neos Therapeutics, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, Supernus, and Corium; received consulting fees from Arbor, Ironshore, Neos Therapeutics, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, Corium, Jazz, Tulex Pharma, and Lumos Pharma; received speaker fees from Takeda\/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Tris, and Supernus; and received writing support from Takeda \/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Purdue, Rhodes, Sunovion, and Tris. JA was an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. at the time of study conduct. PGS, JM, WQ, MC, and AG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"555"}}